Switching to a monthly dose of Berobenatide to help keep weight off after weight loss with semaglutide or tirzepatide

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3 interventional trial evaluating the safety and effectiveness of berobenatide as a maintenance therapy in adults with overweight or obesity who have previously achieved weight loss with semaglutide or tirzepatide. Participants will receive berobenatide and may continue or transition from their prior weight-lossMedication, with monitoring over approximately 11 months. The study enrolls adults without diabetes and excludes those with pancreatitis or certain thyroid cancer syndromes. Primary comparisons assess whether berobenatide helps sustain weight loss and maintains metabolic health after initial improvement with prior GLP-1 receptor agonists.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged ≥18 years.
* Currently taking semaglutide or tirzepatide for obesity management.

Exclusion Criteria:

* Diagnosis of any form of diabetes.
* History of acute or chronic pancreatitis.
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).

Where it's running

• University of Alabama at Birmingham
  Birmingham, Alabama, United States Recruiting
• San Fernando Valley Health Institute
  Canoga Park, California, United States Recruiting
• Velocity Clinical Research - Los Angeles
  Los Angeles, California, United States Recruiting
• Southern California Clinical Research
  Santa Ana, California, United States Recruiting
• Diablo Clinical Research, LLC dba Flourish Research
  Walnut Creek, California, United States Recruiting
• Southern California Retina Specialists
  West Hills, California, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide (PF-08653944) for overweight or obesity in adults

  This study tests whether berobenatide helps adults with overweight or obesity lose weight compared with a placebo.

  Recruiting at 75 sites Phase 3 Pfizer · Canoga Park, California and 79 other locations · NCT07595549

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.